Dudley Capital Management LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.7% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,171 shares of the company’s stock after buying an additional 318 shares during the period. Johnson & Johnson accounts for approximately 4.9% of Dudley Capital Management LLC’s investment portfolio, making the stock its 3rd biggest position. Dudley Capital Management LLC’s holdings in Johnson & Johnson were worth $7,156,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 0.9% in the first quarter. Nisa Investment Advisors LLC now owns 748,842 shares of the company’s stock valued at $116,071,000 after acquiring an additional 6,836 shares during the period. Vaughan Nelson Investment Management L.P. boosted its position in shares of Johnson & Johnson by 21.8% in the first quarter. Vaughan Nelson Investment Management L.P. now owns 903,546 shares of the company’s stock valued at $140,050,000 after acquiring an additional 161,687 shares during the period. Tekla Capital Management LLC boosted its position in shares of Johnson & Johnson by 12.8% in the first quarter. Tekla Capital Management LLC now owns 721,779 shares of the company’s stock valued at $111,876,000 after acquiring an additional 82,100 shares during the period. Scotia Capital Inc. boosted its position in shares of Johnson & Johnson by 1.6% in the fourth quarter. Scotia Capital Inc. now owns 1,105,147 shares of the company’s stock valued at $195,247,000 after acquiring an additional 17,440 shares during the period. Finally, Wisconsin Capital Management LLC boosted its position in shares of Johnson & Johnson by 0.8% in the first quarter. Wisconsin Capital Management LLC now owns 15,723 shares of the company’s stock valued at $2,437,000 after acquiring an additional 127 shares during the period. 67.57% of the stock is owned by institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the stock. Raymond James upped their price objective on shares of Johnson & Johnson from $181.00 to $184.00 and gave the stock an “outperform” rating in a research report on Monday, July 24th. JPMorgan Chase & Co. upped their price objective on shares of Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Morgan Stanley reaffirmed an “equal weight” rating and set a $187.00 price objective on shares of Johnson & Johnson in a research report on Friday, July 21st. Credit Suisse Group upped their price objective on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Finally, Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Eight equities research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Hold” and an average target price of $171.80.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider William Hait sold 14,698 shares of the stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, VP Peter Fasolo sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,163 shares of company stock valued at $7,928,856. 0.20% of the stock is currently owned by company insiders.
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $164.89 on Friday. The business has a 50 day moving average of $166.64 and a 200-day moving average of $161.48. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The company has a market capitalization of $428.54 billion, a P/E ratio of 33.38, a P/E/G ratio of 2.76 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings data on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same quarter in the prior year, the firm posted $2.59 earnings per share. The firm’s revenue was up 6.3% compared to the same quarter last year. On average, equities research analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current year.
Johnson & Johnson Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Shareholders of record on Monday, August 28th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 2.89%. The ex-dividend date of this dividend is Friday, August 25th. Johnson & Johnson’s dividend payout ratio is presently 96.36%.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Articles
- Five stocks we like better than Johnson & Johnson
- How to Calculate Inflation Rate
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Investing in Blue-Chip Stocks
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Roth IRA Calculator: Calculate Your Potential Returns
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
